Ji (2020)
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study
https://doi.org/10.1016/j.jhep.2020.03.044
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141624/
Patient characteristics
BMI (1 unit increase vs. Not applicable)
COVID-19 (severe/fatal)
Odds ratio: 1.300 (1.000-1.800) Adjusted model

China

Retrospective cohort study

Medical records

202

From January 20 through February 17, 2020, consecutive patients admitted to 2 designated COVID-19 Hospitals in China with confirmed COVID-19 and information on NAFLD status were studied.

Two hundred and two consecutive patients with confirmed COVID-19 and information relating to NAFLD status were studied. Male sex (n,%) 113 (55.9); Age (years) 44.5 (34.8–54.1); Age >60 years (n, %) 31 (15.3) Liver injury was observed in 101 (50%) and 152 (75.2%) patients on admission and during hospitalization, respectively. Almost all liver injury was mild with hepatocellular pattern, only 2.6% (4/152) had ductular or mixed pattern. Sixty-seven (33.2%) patients had persistent abnormal liver function from admission to last follow-up. Thirty-nine (19.3%) and 163 (80.7%) had progressive and stable disease, respectively.

0


COVID-19 (severe/fatal)

39

Progression of illness was defined as development of at least one of the following: respiratory rate >=30 breaths/min, resting oxygen saturation <=93% and PaO2/FiO2 <=300 mmHg or worsening of lung CT findings, during the hospitalization period.


Patient characteristics

BMI

BMI (kg/m2)

Not applicable

1 unit increase


Odds ratio

1.300 (1.000-1.800)

No

Yes

Yes

Age, Gender, BMI, Comorbidity ( hypertension, diabetes, cardiovascular disease, chronic lung disease and HIV infections) and Non-Alcoholic Fatty Liver Diseases (NAFLD)


none

Average

Yes